07/11/2016
Leeds, 11 July 2016 – Tissue Regenix Group (AIM:TRX) (‘Tissue Regenix’ or ‘The Group’) the regenerative medical devices company today updates on its strategy for OrthoPure™ XT and XM (porcine tendon and meniscus) market clearance pathways.
The Group is currently undertaking clinical trials within the EU for both products, and due to the success of the clinical data for OrthoPure™ XT to date, is now expected to gain a CE mark for the product by the end of 2016, more than 6 months ahead of schedule. Positive FDA discussions have also encouraged the Group to apply for a US pilot clinical trial, with submission expected in Q4 2016, signalling a key milestone towards gaining regulatory approval for this product in the US.
Tissue Regenix has also established that 510(k) market clearance could be possible for OrthoPure™ XM – a considerably less expensive and time consuming option than previously thought. The EU clinical trial data has proven the implant to be biocompatible, showing integration into the patient’s own tissues, and has been beneficial in highlighting improvements to the implant which Tissue Regenix are investigating further. The Group will only bring to market one version of the product and therefore the current EU trial will be superseded by a new study, with an identical protocol, using the updated implant. However, the current clinical trial will continue to be closed out and the patients currently enrolled will continue to be monitored. It is expected that the process to begin regulatory application for the second trial will begin before the end of 2016.
Antony Odell, CEO Tissue Regenix Group commented: ‘The possibility of earlier EU approval for OrthoPure™ XT, and the potential for a US pilot study, would allow us to access these key markets via a more rapid regulatory route, where sales momentum can be quickly established, particularly with our ‘off the shelf’ alternative to the existing approaches.
Positive data from the OrthoPure™ XM EU clinical trial, and the confirmation of a 510(k) route to the US market, means that we can undertake the additional study to implement improvements and pursue one common version of the product, expected for launch within the EU during 2018, and allow us to initiate the work required for US regulatory approval.’
For more Information:
Tissue Regenix Group plc
Caitlin Pearson Corporate Communications Officer
Tel: 0330 430 3073
Jefferies International Ltd
Simon Hardy / Harry Nicholas
Tel: 020 7029 8000
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®’) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States – ‘Tissue Regenix Wound Care Inc.’, as part of its commercialisation strategy for its dCELL® technology platform.
Tissue Regenix Group plc published this content on 11 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 July 2016 06:13:17 UTC.
ORIGINAL DOCUMENThttp://otp.investis.com/clients/uk/tissueregenix1/rns/regulatory-story.aspx?cid=208&newsid=758816
PUBLIC PERMALINKhttp://www.publicnow.com/view/CE512C009A6ADC182FA44C5CC9B27A11B34B60CB
share with twitter share with LinkedIn share with facebook share via e-mail
